A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Eligible for screening study DCP 001
EA7222 is closed to accrual to the Undifferentiated Pleomorphic Sarcoma (UPS) Cohort, effective July 31, 2026, at 5:00 pm ET.
